Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review

Eur J Surg Oncol. 2013 Apr;39(4):311-9. doi: 10.1016/j.ejso.2012.12.018. Epub 2013 Jan 23.

Abstract

Background: Isolated limb perfusion (ILP) may provide a limb salvage option for locally advanced soft tissue sarcoma (STS) not amenable to local resection.

Methods: A systematic review was performed for studies reporting outcome of ILP for locally advanced STS performed after 1980 in patients aged ≥ 12 years old. The main endpoints were tumour response and limb salvage rates. Complication and recurrence rates were secondary endpoints.

Results: Eighteen studies were included, providing outcomes for 1030 patients. Tumour necrosis factor-alpha with melphalan was the commonest chemotherapy regime. When reported, 22% of cases achieved a complete tumour response (216/964, 15 studies) with an overall response rate of 72% (660/911, 15 studies). At median follow-up times ranging between 11 and 125 months, the limb salvage rate was 81% in patients who otherwise would have been subjected to amputation. However, 27% of patients suffered local recurrence and 40% suffered distant failure. ILP was associated with severe locoregional reactions in 4% (22/603) of patients. Amputation due to complications within 30 days was necessary in 1.2% of cases (7/586, nine studies). There was insufficient evidence to determine the effect of ILP on survival.

Conclusion: ILP induces a high tumour response rate, leads to a high limb salvage rate but is associated with a high recurrence rate. It provides a limb salvage alternative to amputation when local control is necessary.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Amputation, Surgical / statistics & numerical data
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemotherapy, Cancer, Regional Perfusion* / adverse effects
  • Humans
  • Limb Salvage*
  • Melphalan / administration & dosage
  • Neoplasm Recurrence, Local
  • Recurrence
  • Sarcoma / drug therapy*
  • Soft Tissue Neoplasms / drug therapy*
  • Survival Analysis
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / administration & dosage

Substances

  • Tumor Necrosis Factor-alpha
  • Melphalan